ABT FY 2023 Earnings Report — Abbott Laboratories Revenue & Financial Results | Market Cap Arena

Abbott LaboratoriesABT

FY 2023 Earnings

Reported February 16, 2024

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2023	Prior Q	FY 2022	QoQ Change	YoY Change
Revenue	$40.1B	—	$43.7B	—	-8.1%
Op. Income	$6.4B	—	$8.4B	—	-23.0%
Gross Margin	50.0%	—	51.1%	—	-1.2pp
Net Margin	14.3%	—	15.9%	—	-1.6pp
EPS (Diluted)	$3.27	—	$3.91	—	-16.4%
Free Cash Flow	$5.1B	—	$7.8B	—	-35.2%

Revenue Flow

Item	Amount
REVENUE	$40.1B
Cost of Revenue	$20.1B
GROSS PROFIT	$20.0B
R&D Expenses	$2.7B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$10.9B
Other Expenses	$0
Operating Expenses	$13.6B
Cost & Expenses	$33.7B
OPERATING INCOME	$6.4B
Interest Income	$385M
Interest Expense	$698M
Other Income/Expenses	$229M
INCOME BEFORE TAX	$6.7B
Income Tax Expense	$941M
Net Income from Continuing Ops	$5.7B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$5.7B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$5.7B
D&A	$3.2B
EBIT	$7.4B
EBITDA	$10.6B
EPS	$3
EPS Diluted	$3

Income Statement

Item	Amount
REVENUE	$40.1B
Cost of Revenue	$20.1B
GROSS PROFIT	$20.0B
R&D Expenses	$2.7B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$10.9B
Other Expenses	$0
Operating Expenses	$13.6B
Cost & Expenses	$33.7B
OPERATING INCOME	$6.4B
Interest Income	$385M
Interest Expense	$698M
Other Income/Expenses	$229M
INCOME BEFORE TAX	$6.7B
Income Tax Expense	$941M
Net Income from Continuing Ops	$5.7B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$5.7B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$5.7B
D&A	$3.2B
EBIT	$7.4B
EBITDA	$10.6B
EPS	$3
EPS Diluted	$3

Cash Flow Statement

Item	Amount
Net Income	$5.7B
Depreciation & Amortization	$3.2B
Stock-Based Compensation	$644M
Deferred Income Tax	$0
Other Non-Cash Items	$126M
Change in Working Capital	-$2.5B
OPERATING CASH FLOW	$7.3B
Capital Expenditure	-$2.2B
Acquisitions (Net)	-$837M
Purchases of Investments	-$159M
Sales/Maturities of Investments	$43M
Other Investing Activities	$22M
NET CASH FROM INVESTING	-$3.1B
Net Debt Issuance	-$2.5B
Common Stock Repurchased	-$1.2B
Common Dividends Paid	-$3.6B
Other Financing Activities	$167M
NET CASH FROM FINANCING	-$7.1B
FREE CASH FLOW	$5.1B
Net Change in Cash	-$3.0B

Balance Sheet

Item	Amount
Cash & Equivalents	$6.9B
Short-Term Investments	$383M
Net Receivables	$6.6B
Inventory	$6.6B
Other Current Assets	$2.3B
TOTAL CURRENT ASSETS	$22.7B
PP&E (Net)	$11.3B
Goodwill	$23.7B
Intangible Assets	$8.8B
Long-Term Investments	$799M
Tax Assets	$0
Other Non-Current Assets	$6.0B
TOTAL NON-CURRENT ASSETS	$50.5B
TOTAL ASSETS	$73.2B
Account Payables	$4.3B
Short-Term Debt	$1.3B
Deferred Revenue	$0
Other Current Liabilities	$6.1B
TOTAL CURRENT LIABILITIES	$13.8B
Long-Term Debt	$13.6B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$1.2B
Other Non-Current Liabilities	$4.8B
TOTAL NON-CURRENT LIABILITIES	$20.5B
TOTAL LIABILITIES	$34.4B
Common Stock	$24.9B
Additional Paid-In Capital	$0
Retained Earnings	$37.6B
Treasury Stock	-$16.0B
Accum. Other Comp. Income	-$7.8B
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$38.6B
Minority Interest	$224M
TOTAL EQUITY	$38.8B
TOTAL LIABILITIES & EQUITY	$73.2B
Total Debt	$15.9B
Net Debt	$9.0B